Anticoagulation of Choice in DVT
Direct oral anticoagulants (DOACs)—specifically apixaban or rivaroxaban—are the first-line anticoagulants for acute deep vein thrombosis in otherwise healthy adults, with a minimum treatment duration of 3 months. 1
First-Line Anticoagulant Selection
Apixaban and rivaroxaban are strongly preferred over all other anticoagulants because they require no parenteral lead-in, demonstrate superior safety compared with warfarin, provide equivalent or better efficacy, and enable immediate outpatient initiation. 2, 1
- Apixaban dosing: 10 mg orally twice daily for 7 days, then 5 mg twice daily for the remaining treatment period—no heparin bridge required. 1
- Rivaroxaban dosing: 15 mg orally twice daily with food for 21 days, then 20 mg once daily with food—no heparin bridge required. 1
Edoxaban and dabigatran are acceptable alternatives but less convenient because they mandate 5–10 days of parenteral anticoagulation (LMWH, fondaparinux, or unfractionated heparin) before the first oral dose can be given. 2, 1, 3
When DOACs Cannot Be Used
If a DOAC is contraindicated, initiate low-molecular-weight heparin (LMWH) or fondaparinux immediately and overlap with warfarin starting on day 1. 2, 1
- LMWH (enoxaparin): 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily. 1
- Fondaparinux (weight-based): 5 mg if <50 kg, 7.5 mg if 50–100 kg, 10 mg if >100 kg, subcutaneously once daily. 1
- Continue the parenteral agent for at least 5 days and until the INR is ≥2.0 for a minimum of 24 hours before stopping the parenteral drug. 2, 1
- Target warfarin INR of 2.5 (therapeutic range 2.0–3.0) for the entire treatment course. 2, 1
DOAC contraindications include:
- Confirmed antiphospholipid syndrome (use adjusted-dose warfarin instead; DOACs increase recurrent thrombosis risk). 2, 1
- Severe renal impairment (creatinine clearance <30 mL/min). 1
- Pregnancy. 4
- Mechanical prosthetic heart valves. 3
Treatment Duration Algorithm
Stop at 3 Months
Provoked DVT with a major transient risk factor (e.g., surgery, major trauma, hospitalization): Discontinue anticoagulation exactly at 3 months; annual recurrence risk is <1%, and extending therapy provides no additional benefit. 2, 1
Provoked DVT with a minor transient risk factor (e.g., estrogen therapy, prolonged travel, minor injury): Stop at 3 months in most patients; extend only if bleeding risk is exceptionally low. 2, 1
Continue Indefinitely (No Scheduled Stop Date)
Unprovoked DVT with low-to-moderate bleeding risk: Annual recurrence risk exceeds 5–10% after cessation; offer indefinite extended-phase anticoagulation with a DOAC because the recurrence risk outweighs bleeding risk. 2, 1
DVT with persistent risk factors (active cancer, chronic immobility, antiphospholipid syndrome, inherited thrombophilia): Indefinite anticoagulation is mandatory as long as the risk factor persists. 2, 1
Second unprovoked DVT: Lifelong anticoagulation is required regardless of bleeding risk. 2, 1
Reassess the risk-benefit balance at least annually and after any major change in health status. 2, 1
Special Populations
Cancer-Associated Thrombosis
Oral factor Xa inhibitors (apixaban, rivaroxaban, or edoxaban) are preferred over LMWH for cancer-associated DVT, based on moderate-certainty evidence. 2, 1
In patients with luminal gastrointestinal malignancies (esophageal, gastric, colorectal), avoid edoxaban or rivaroxaban due to higher GI bleeding risk; use apixaban or LMWH instead. 2, 1
Antiphospholipid Syndrome
Use adjusted-dose warfarin (target INR 2.5) instead of DOACs; DOACs are associated with increased recurrent thrombosis in confirmed APS. 2, 1
Isolated Distal (Calf) DVT
In patients without severe symptoms or high-risk features (no active cancer, prior VTE, or extensive clot burden), perform serial duplex ultrasound every 2 weeks for 2 weeks instead of immediate anticoagulation. 1
If proximal extension occurs, anticoagulation is mandatory. 1
Patients with severe symptoms or high-risk features should receive immediate anticoagulation. 1
When anticoagulation is started for distal DVT, treat for 3 months—the same duration as for proximal DVT. 1
Treatment Setting and Mobilization
Most patients with uncomplicated DVT can be managed at home rather than hospitalized, provided they have stable living conditions and reliable follow-up. 2, 1, 5
Encourage early ambulation immediately after anticoagulation initiation; prolonged bed rest does not reduce pulmonary embolism risk and may worsen outcomes. 2, 1, 5
Interventions to Avoid
Do not use catheter-directed thrombolysis, systemic thrombolysis, or surgical thrombectomy for routine DVT; anticoagulation alone is sufficient. 1, 5
Reserve thrombolytic therapy only for limb-threatening circulatory compromise (phlegmasia cerulea dolens) or highly selected young patients with acute iliofemoral DVT who have severe symptoms and low bleeding risk. 1, 6
Do not place IVC filters routinely; they are indicated only when anticoagulation is absolutely contraindicated (e.g., active major bleeding, recent neurosurgery). 2, 1, 5
Critical Pitfalls to Avoid
Never discontinue anticoagulation before completing 3 months for any acute DVT; early cessation markedly raises recurrence and extension risk. 2, 1
Never prescribe DOACs in confirmed antiphospholipid syndrome; use adjusted-dose warfarin (target INR 2.5) instead. 2, 1
Never place IVC filters in addition to anticoagulation for routine DVT management; filters do not reduce mortality and increase long-term DVT risk. 2, 1, 5
Never stop parenteral anticoagulation before achieving a therapeutic INR (≥2.0 for ≥24 hours) when transitioning to warfarin. 2, 1
Never enforce prolonged bed rest based on outdated concerns about embolization; early ambulation is safe and beneficial. 1, 5